Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Texas MPN Workshop 2022 | CHIP and implications for myeloproliferative neoplasms

Rafael Bejar • 10 Nov 2022
Texas MPN Workshop 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, gives a presentation on clonal hematopoiesis of indeterminate potential (CHIP) and implications for myeloproliferative neoplasms (MPNs) at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

More from Rafael Bejar

The role of chronic inflammation in clonal hematopoiesis and the development of MDS
1:53
The role of chronic inflammation in clonal hematopoiesis and the development of MDS
Rafael Bejar • 26 Aug 2022
The role of the innate immune system in MDS pathogenesis
1:32
The role of the innate immune system in MDS pathogenesis
Rafael Bejar • 26 Aug 2022
The importance of genomic testing in MPNs and other myeloid malignancies
1:45
The importance of genomic testing in MPNs and other myeloid malignancies
Rafael Bejar • 26 Aug 2022
Using CHIP to encourage early intervention in disease
1:29
Using CHIP to encourage early intervention in disease
Rafael Bejar • 26 Aug 2022

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Rafael Bejar • 7 Dec 2025
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Rafael Bejar • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Rafael Bejar • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Rafael Bejar • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals